Naya Biosciences Inc (NAYA)

$2.20 +0.17 (8.37%)
Market Cap 1.22M
Revenue (ttm) 3.02M
Net Income (ttm) -8.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -265.89%
Debt to Equity Ratio -56.50
Volume 188,200
Avg Vol 71,821
Day's Range N/A - N/A
Shares Out 666,000.00
Stochastic %K 56%
Beta 2.03
Analysts Strong Sell
Price Target $6.00

Company Profile

INVO Fertility, Inc., a life science portfolio company, develops clinical stage assets to treat patients with fertility, oncology, and autoimmune diseases. The company operates in two divisions, NAYA Women's Health and NAYA Therapeutics. Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma, as well as solid and pediatric tumors; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma...

Industry: Medical Devices
Sector: Healthcare
Phone: 978-878-9505
Address:
5582 Broadcast Court, Sarasota, United States
rlkloehn
rlkloehn Jun. 18 at 4:34 AM
$NAYA https://youtu.be/CzMG6_hOB5w?si=Fxx8Dvoby9u4ePWo
0 · Reply
bruceleeboy
bruceleeboy Jun. 17 at 8:04 PM
$IMNPQ.DL0922 $NAYA For those interested in science updates. Naya TX is moving along. NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline With First-in-Class GPC3-Targeted Astatine-211 Alpha Radioimmunotherapy https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-cla-1040403
0 · Reply
rlkloehn
rlkloehn Jun. 13 at 6:37 AM
$NAYA View profile for Daniel Teper Daniel Teper Founder and CEO @ NAYA Therapeutics | INSEAD MBA, PharmD 2d Edited MIT CEO LONGWOOD HEALTHCARE LEADERS June 17-18, 2025 MIT Koch Institute for Integrative Cancer Research Delighted to join the Capital Markets Outlook panel with Jason Fenton Co-Head of Equity Capital Markets at Cantor Fitzgerald, Gaurav Shah, MD CEO of Rocket Pharmaceuticals, Sabrina Johnson CEO of Daré Bioscience, Inc., and Vinny Jindal CEO of Secretome Therapeutics. As NAYA Therapeutics exits a reverse merger and refocuses on #bispecifics and #radioimmunotherapy in #oncology, we look at Capital Markets that are increasingly binary with larger private and public transactions supporting the potential winners. #China's emergence as a source of innovative drugs and transactions, speed and quality of execution by US and EU companies requires strong capitalizations leaving behind the uncertainties of micro-cap markets.
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:42 AM
$NAYA Zero contact info. Fishy .
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:41 AM
$NAYA This one. https://www.florida-biotech.com
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:41 AM
$NAYA Looks like Florida Biotech is keepijg busy.
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:40 AM
https $NAYA
0 · Reply
rlkloehn
rlkloehn Jun. 6 at 8:11 PM
$NAYA Bispecifics are already ruling immuno-oncology ! The race is on with big pharma paying top dollars to defend the Keytruda ( Merck) and opdivo (BMS) ftanchises and others soon to participate in the emerging $100 B PD1xVEGF opportunity. At the same time #Merus a $4 B market cap biotech delivers 80% response with its EGFRxLGR5 bispecific in head and neck cancer and raises $300M. The biology and the growing clinical data support the superiority of bispecifics over legacy monoclonals. The emerging winners will move fast, design and implement clinical trials based on AI predictive models to maximize clinical outcomes and embraces combinations with other modalities such as #ADC and #RIT. This is our playbook at NAYA Therapeutics with an initial focus on hepatocellular Carcinoma (#HCC)with two complementary bispecifics and a RIT and in Multiple Myeloma where #bispecifics are starting to position themselves to dethrone Darzalex and ahead of CAR-Ts for broad use in the community.
1 · Reply
PennyScam
PennyScam Jun. 5 at 2:12 PM
$NAYA Love those inducements. Hilarious. Cuckoo Kenny
0 · Reply
PennyScam
PennyScam Jun. 5 at 1:15 PM
$NAYA Funny….. We will pay. We won’t pay. We will pay. We won’t pay. Hilarious.
0 · Reply
Latest News on NAYA
No data available.
rlkloehn
rlkloehn Jun. 18 at 4:34 AM
$NAYA https://youtu.be/CzMG6_hOB5w?si=Fxx8Dvoby9u4ePWo
0 · Reply
bruceleeboy
bruceleeboy Jun. 17 at 8:04 PM
$IMNPQ.DL0922 $NAYA For those interested in science updates. Naya TX is moving along. NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline With First-in-Class GPC3-Targeted Astatine-211 Alpha Radioimmunotherapy https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-expands-its-hepatocellular-carcinoma-hcc-pipeline-with-first-in-cla-1040403
0 · Reply
rlkloehn
rlkloehn Jun. 13 at 6:37 AM
$NAYA View profile for Daniel Teper Daniel Teper Founder and CEO @ NAYA Therapeutics | INSEAD MBA, PharmD 2d Edited MIT CEO LONGWOOD HEALTHCARE LEADERS June 17-18, 2025 MIT Koch Institute for Integrative Cancer Research Delighted to join the Capital Markets Outlook panel with Jason Fenton Co-Head of Equity Capital Markets at Cantor Fitzgerald, Gaurav Shah, MD CEO of Rocket Pharmaceuticals, Sabrina Johnson CEO of Daré Bioscience, Inc., and Vinny Jindal CEO of Secretome Therapeutics. As NAYA Therapeutics exits a reverse merger and refocuses on #bispecifics and #radioimmunotherapy in #oncology, we look at Capital Markets that are increasingly binary with larger private and public transactions supporting the potential winners. #China's emergence as a source of innovative drugs and transactions, speed and quality of execution by US and EU companies requires strong capitalizations leaving behind the uncertainties of micro-cap markets.
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:42 AM
$NAYA Zero contact info. Fishy .
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:41 AM
$NAYA This one. https://www.florida-biotech.com
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:41 AM
$NAYA Looks like Florida Biotech is keepijg busy.
0 · Reply
PennyScam
PennyScam Jun. 10 at 1:40 AM
https $NAYA
0 · Reply
rlkloehn
rlkloehn Jun. 6 at 8:11 PM
$NAYA Bispecifics are already ruling immuno-oncology ! The race is on with big pharma paying top dollars to defend the Keytruda ( Merck) and opdivo (BMS) ftanchises and others soon to participate in the emerging $100 B PD1xVEGF opportunity. At the same time #Merus a $4 B market cap biotech delivers 80% response with its EGFRxLGR5 bispecific in head and neck cancer and raises $300M. The biology and the growing clinical data support the superiority of bispecifics over legacy monoclonals. The emerging winners will move fast, design and implement clinical trials based on AI predictive models to maximize clinical outcomes and embraces combinations with other modalities such as #ADC and #RIT. This is our playbook at NAYA Therapeutics with an initial focus on hepatocellular Carcinoma (#HCC)with two complementary bispecifics and a RIT and in Multiple Myeloma where #bispecifics are starting to position themselves to dethrone Darzalex and ahead of CAR-Ts for broad use in the community.
1 · Reply
PennyScam
PennyScam Jun. 5 at 2:12 PM
$NAYA Love those inducements. Hilarious. Cuckoo Kenny
0 · Reply
PennyScam
PennyScam Jun. 5 at 1:15 PM
$NAYA Funny….. We will pay. We won’t pay. We will pay. We won’t pay. Hilarious.
0 · Reply
PennyScam
PennyScam Jun. 5 at 1:08 PM
$NAYA Okie dokie.
0 · Reply
PennyScam
PennyScam Jun. 5 at 1:05 PM
$NAYA Always interesting to know.
0 · Reply
PennyScam
PennyScam Jun. 5 at 12:59 PM
$NAYA Still have a good wait ahead people. No liquidity for a while Longs. Enjoy your summer. Cuckoo Penny
0 · Reply
PennyScam
PennyScam Jun. 5 at 12:58 PM
$NAYA Fun times. 90 days from shareholder approval.
0 · Reply
rlkloehn
rlkloehn Jun. 2 at 1:03 AM
$NAYA promises, promises NY-303, a GPC3 x NKp46 bifunctional antibody for the treatment of HCC with a unique mechanism of action targeting non-responders to the current immunotherapy standard of care (70-85% of the current treatable market), cleared to enroll patients in a Phase I/IIa monotherapy trial in H2 2025, NY-500, an AI-optimized PD-1 x VEGF bifunctional antibody aiming to be the first PD-1 x VEGF to market in HCC, with translational clinical and preclinical data in 2025 and Phase I/II in HCC to be initiated in early 2026, and NY-338, a CD38 x NKp46 bifunctional antibody for the treatment of multiple myeloma with a unique mechanism of action enhancing safety & efficacy and a differentiated profile to daratumumab and T-Cell engagers, aiming to enroll patients in its Phase I/II clinical trials in early 2026
1 · Reply
PennyScam
PennyScam May. 30 at 12:59 PM
$NAYA Who cares about valuation. People care more about liquidity. Fuck the valuation. And stop saying, “rapidly unlock its valuation”. I swear you, you say that statement one more time …..argh. Be more original in your wording. Unless of course you are being repetitive for a reason. That couldn’t be the case right? No signals being given right? lol. You and your band of thieves are fucking idiots Teper. Let’s see if Satellos or ESHA comes into the picture. I’m thinking Satellos is first. Crazy Kenny
0 · Reply
PennyScam
PennyScam May. 30 at 12:49 PM
$NAYA Another media release. More exchanges coming. Another crooked partnership used to do share exchange and finance Naya / Cytovia. You all know remember how long it took to do the last one. Couple years to do a micro deal. lol. Here comes Satellos Bioscience or ESHA partnership. Here comes Cytovia. Here comes another shell game. More crooked companies. More discount retailers. More crooked investors coming into something that has had zero liquidity for 10 plus years. Crazy Kenny
0 · Reply
PennyScam
PennyScam May. 30 at 1:05 AM
$NAYA Everything pushed now to 2026. Hilarious. Crazy K
0 · Reply
PennyScam
PennyScam May. 30 at 1:02 AM
$NAYA Snooze fest…….crazy k
0 · Reply
PennyScam
PennyScam May. 30 at 1:02 AM
$NAYA https://www.accessnewswire.com/newsroom/en/biotechnology/naya-therapeutics-enters-into-definitive-agreements-to-regain-full-rights-to-next-gen-1030292
0 · Reply
bruceleeboy
bruceleeboy May. 29 at 2:26 PM
$IMNPQ.DL0922 $NAYA Tepers talking partnership…
1 · Reply
bruceleeboy
bruceleeboy May. 26 at 11:50 PM
$IMNPQ.DL0922 $MSCLF Satellos will likely do the 15:1 reverse split and drop OS to about 11M. Longs there may soon experience an Immune response. Timing is interesting. $NAYA/ $IVF and $CLLS have their annuals June 25th & 26th.
2 · Reply